Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
- PMID: 27392220
- DOI: 10.1016/j.stem.2016.06.005
Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
Abstract
Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment on
-
Adenovirus mediated alpha interferon (IFN-alpha) gene transfer into CD34+ cells and CML mononuclear cells.Stem Cells. 1997;15(5):386-95. doi: 10.1002/stem.150386. Stem Cells. 1997. PMID: 9323802
-
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8. Nature. 2016. PMID: 27281222 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical